Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.

In the present study, except for a nonsignificant trend toward decrease from baseline to day 17 (from median 6.1 to 4.4 ng/mL), we did not observe consistent overall reductions in HMGB1 serum levels ( Figure 6 ).

also in 5,406 other papers